Trump’s mass deportation raids result in 655% spike in arrests of terrorists roaming US

 The Trump administration’s mass deportation raids have nabbed more than 200 known or suspected terrorists since January — including one of India’s “most wanted,” who is accused of masterminding a grenade attack on a cop there and has ties to a US-designated terrorist organization in Pakistan.

Since President Trump’s inauguration on Jan. 20, Immigration and Customs Enforcement officers have arrested 219 known or alleged terrorists, marking a 655% increase from the same period last year when 29 such arrests were made under former President Joe Biden, according to new Homeland Security data obtained by The Post.

3

ICE agents nabbed suspected Indian terrorist Harpreet Singh last week in Sacramento, California.ICE

Among the dozens of terrorists swept up in Trump’s raids was Harpreet Singh, a citizen of India who entered the US illegally on Jan. 27, 2022 by crossing from Mexico into Arizona and was swiftly released into the country by Border Patrol agents with a future court date, a DHS official said.

The Biden administration is to blame for allowing Singh to roam the country for more than three years, DHS Assistant Secretary Tricia McLaughlin told The Post.

“The Biden administration not only let a wanted terrorist into our country, but after he was arrested by Border Patrol agents, they released him into the interior of our country,” she charged.

“While shocking, it’s not surprising given the Biden administration routinely released unvetted terrorists and criminals into American communities,” she added.

Singh is one of his home country’s “most wanted men” for providing terrorist funds, recruitment and planning of a grenade attack on an Indian Police Station and on a retired Punjab cop’s house with the intent to kill and instill fear among law enforcement officers, according to DHS.

He is also wanted for multiple violent extortion and threatening operations in India.

3

The White House said ICE nabbed a Jordanian suspected ISIS terrorist.White House

3

An Afghan man believed to have terror ties was also scooped up by ICE.The White House

Indian officials believe Singh is a senior operative directly linked to Harwinder Singh Rinda, an infamous figure in the Pakistan-based Babbar Khalsa International (BKI), which the US designated a foreign terrorist organization in 2002.

The religious extremist terror group started in the late 1970s and has taken part in assassinations of politicians, armed attacks and bombings, according to DHS.

But it is not clear whether or not border agents were aware of Singh’s terror ties before they let him go in 2022.

ICE was able to nab Singh in Sacramento last week.

“He had been evading capture by using untraceable burner phones and encrypted applications,” the FBI said in a statement announcing his arrest.

The Trump administration vows to continue to collar the terrorists “who have operated with impunity on American soil,” McLaughlin said.

“Under President Trump and Secretary Noem’s leadership, ICE is unleashed to remove these violent criminals from America’s streets and put an end to catch and release,” she said.

https://nypost.com/2025/04/22/us-news/trumps-mass-deportation-raids-result-in-655-spike-in-arrests-of-terrorists-roaming-us-including-one-of-indias-most-wanted/

US defense contractors mostly maintain forecasts despite Trump tariffs

 Major U.S. defense contractors are mostly maintaining their financial forecasts for 2025, saying it is too soon to understand the impact of U.S. President Donald Trump's tariffs.

Lockheed Martin, the largest defense firm, reaffirmed its forecasts for the year on Tuesday, buoyed by resilient demand for its missile systems and fighter jets. Similarly, Northrop Grumman said its profit margins may narrow, but stuck with its sales prediction, indicating some confidence in the face of trade tensions.

"We do not see, at this point in time, significant risk to our company related to the trade policies as we understand them today," Northrop CEO Kathy Warden told analysts. "We're going to monitor that closely and we're already taking action to account for and mitigate the risks that we do see, particularly in availability of certain components that we need for delivering on our programs."

RTX Corp, formerly known as Raytheon Technologies, broke ranks by expressing concern about potentially $850 million in reduced profits from new levies on metals and China. This divergence highlights the varying impacts of trade policies across the defense and commercial aerospace sectors.

RTX has large commercial aerospace businesses that make jet interiors and engines.

The defense industry, like other sectors with complex manufacturing operations, is grappling with the potential effects of a global trade war. The situation has pressured an already strained supply chain, forcing companies to reassess their strategies and cost structures.

Despite these challenges, the sector continues to benefit from a surge in global weaponry demand, fueled by the Russian war in Ukraine and conflict in the Middle East. This increased demand has helped offset some of the uncertainties stemming from trade disputes. However, RTX's concern signals the industry is not immune to trade pressures, highlighting the complex interplay between defense spending, international relations, and economic policies.

A higher U.S. defense budget, suggested by Defense Secretary Pete Hegseth in an April 7 social media post, would benefit contractors' revenues while providing some stability and growth, even amid an uncertain economic outlook.

Trump's review of military equipment export rules, aimed at easing restrictions, could potentially boost revenues for U.S. contractors. However, this comes as some allies, including Canada and the European Union, are reconsidering their reliance on U.S. defense equipment due to trade tensions and shifting geopolitical alliances.

The European Union has outlined plans to shore up its own defense capabilities to reduce reliance on the U.S. by 2030, meaning any role for companies outside the bloc could diminish.

Northrop Grumman posted a 49% drop in first-quarter profit and missed sales expectations, as the U.S. contractor booked losses on its B-21 stealth bomber program due to higher manufacturing costs, sending its shares down 12%.

Lockheed reported higher first-quarter profit, boosting shares more than 2%. Lockheed quarterly earnings per share of $7.28 beat Wall Street analyst expectations of $6.34.

Collins Aerospace, RTX's aerospace and avionics arm, posted an 8% rise in revenue that touched $7.22 billion in the quarter, while the Pratt and Whitney unit, which makes engines for Airbus', A320neo jets, saw sales rise 14%.

Raytheon, RTX's defense unit, reported a 5% fall in sales year-over-year, primarily driven by the divestiture of its cybersecurity, intelligence and services business completed last year.

https://www.msn.com/en-ie/money/markets/us-defense-contractors-mostly-maintain-forecasts-despite-trump-tariffs/ar-AA1DpdIK

Tesla salvages first-quarter profit margins as car sales skid

 A battered Tesla topped rock-bottom profitability expectations on Tuesday and said it was on track to produce an affordable car, offering some hope to investors as sales dropped. It said it would have to reassess its growth forecast in three months.

The electric-vehicle maker said in its first-quarter results that it would revisit its annual outlook in its next earnings report due to "the impacts of shifting global trade policy."

It said its plans to release a cheaper car in the first half of 2025, and launch a robotaxi fleet in Austin, Texas, both remained on track.

Tesla has faced a troubling few months as deliveries of its aging lineup of EVs have nosedived, CEO Elon Musk's political activities have drawn protests, and its stock has nearly halved from its December peak. 

Many investors are calling for Musk to leave his work as U.S. President Donald Trump's adviser and get back to managing Tesla more closely. Tesla showrooms have been vandalized, and sales in California - its largest U.S. market - have fallen sharply.

But its stronger-than-expected margin in the first quarter offers some relief, as its cost of making and selling vehicles dropped over 17% year over year, driven by lower raw material prices and reduced expenses of ramping up Cybertruck production.

Automotive gross margin for the period, excluding regulatory credits, was 12.5%, according to Reuters calculations, compared with expectations of 11.8%, according to 21 analysts polled by Visible Alpha. 

But the company said: "Uncertainty in the automotive and energy markets continues to increase as rapidly evolving trade policy adversely impacts the global supply chain and cost structure of Tesla and our peers. This dynamic, along with changing political sentiment, could have a meaningful impact on demand for our products in the near-term."

It added that it was "difficult to measure the impacts of shifting global trade policy on the automotive and energy supply chains, our cost structure and demand for durable goods and related services," which would prompt a reevaluation of its annual forecast. 

The electric vehicle maker reported revenue of $19.34 billion for the January-March quarter, compared with estimates of $21.11 billion, according to data compiled by LSEG.

Tesla reported earlier this month that deliveries in the January-March period slid 13%, as the company lost ground to Chinese rivals, and Musk's political actions as a close adviser to U.S. President Donald Trump have damaged the brand.

The company's stock, which closed at $237.97 on Tuesday, has nearly halved from its December peak. It was little changed in after-market trading.

The EV maker scrapped plans for a brand-new, low-cost model last year, opting instead to produce cheaper variants using existing platforms and assembly lines. Reuters reported exclusively on Friday that Tesla delayed plans to start production of a more affordable Model Y crossover by at least a few months.

Musk promised driverless ride-hailing services to the public in Texas by June, and in California for later this year. To that end, Tesla has been seeking regulatory approvals, but there are serious concerns about safety and related litigation risks that could come with deploying unproven driverless technology on public streets.

Analysts expect a second straight annual decline in Tesla deliveries in 2025, despite efforts to boost sales through incentives like free charging and Full Self-Driving features.

Tesla also recalled all Cybertrucks delivered since late 2023 and launched a lower-priced $70,000 version of the vehicle. It has been discounting unsold inventory of the electric pickup truck in recent weeks.

Tariff tensions add further uncertainty. Tesla has paused some China-sourced component imports after U.S. tariffs on the Asian country rose to 145%, Reuters reported. China has responded with tariffs of its own, leading Tesla to suspend new Model S and X orders in the country.

https://www.marketscreener.com/quote/stock/TESLA-INC-6344549/news/Tesla-salvages-first-quarter-profit-margins-as-car-sales-skid-49674000/

 Bristol Myers Squibb's Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with schizophrenia.

The company said Tuesday a Phase 3 trial of Cobenfy as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale total score compared to a placebo with an atypical antipsychotic at week six.

The results missed the threshold for statistical significance for the primary endpoint, the company said.

Preliminary analyses suggest the treatment was associated with improved schizophrenia symptoms compared to the placebo treatment for certain patients.

A post-hoc subgroup analysis showed there was a notable difference in response between subjects treated with risperidone as a background therapy and those treated with other background antipsychotics.

The company said it plans to speak with regulators about potential next steps.

Shares fell 5.6% to $47.03 on Tuesday in after-hours trading. Shares have risen 1% over the last 12 months through Tuesday's close.

https://www.morningstar.com/news/dow-jones/202504229920/bristol-myers-squibbs-schizophrenia-treatment-falls-flat

Icahn builds 34% economic interest in Bausch Health

 Billionaire Carl Icahn has built an economic interest covering about 34% of Bausch Health's shares, according to a filing on Tuesday, days after the pharmaceutical firm adopted a "poison pill" to ward off hostile takeovers.

U.S.-listed shares of Bausch Health, the parent company of contact lens maker Bausch + Lomb, rose nearly 8% to $5.09 in early trading.

In addition to owning 9.4% of the company's shares, Icahn has exposure to an additional 24.6%, or 90.72 million shares through cash-settled equity swap agreements, Bausch Health said.

Such financial contracts only allow an investor to benefit from stock movements without actually owning the shares. According to Icahn, the agreements do not give him control over voting on the additional shares.

Bausch Health, which has engaged financial advisors to help finance its large debt, last week adopted a shareholders' rights plan, or a "poison pill", to prevent investors from acquiring a more than 20% stake.

At the time, the company said the move was not in response to any specific proposals and it was not aware of any threatened take-over bids.

It reported total liabilities of nearly $27 billion at the end of last year.

In a supplement to its proxy filing, the company said Icahn refused to provide copies of the swap agreements to Bausch's lawyers, but has said they were accumulated through more than 100 trades that took place between May 2021 and September 2023.

The equity swap agreements mature on February 28, 2028 but can be terminated earlier in exchange for cash settlement, Icahn told Bausch's lawyers.

The company's chairman John Paulson also holds $50 million worth of bonds, which he plans to dispose off to eliminate "even the appearance of a conflict of interest," Bausch disclosed in its filing.

https://finance.yahoo.com/news/bausch-health-says-carl-icahn-125408391.html

Atossa Therapeutics secures new patent for breast cancer treatment

 Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company with a current market capitalization of $82.23 million, announced today that it has been granted a new patent by the United States Patent and Trademark Office (USPTO). The patent, U.S. Patent No. 12,275,684, relates to enteric oral formulations of (Z)-endoxifen, a Selective Estrogen Receptor Modulator (SERM), and methods for treating hormone-dependent breast and reproductive tract disorders.

The patent aims to strengthen Atossa’s intellectual property portfolio around its proprietary (Z)-endoxifen formulations, which are being developed as a targeted therapy for hormone receptor-positive breast cancer. According to Steven Quay, M.D., Ph.D., President and CEO of Atossa, the patent issuance is a significant milestone in the company’s mission to advance treatments for breast cancer and underscores their dedication to providing effective therapeutic options to patients. While the company holds more cash than debt and maintains a strong current ratio of 14.99, it is currently burning through cash rapidly - a crucial factor for investors to monitor.

(Z)-endoxifen is considered one of the most potent SERMs for estrogen receptor inhibition and may degrade estrogen receptors. It has shown efficacy in patients resistant to other hormonal treatments and targets PKCβ1, an oncogenic protein, at clinically attainable blood concentrations. Atossa’s oral formulation of (Z)-endoxifen is designed to bypass the stomach to prevent conversion to the inactive (E)-endoxifen, and it has been well tolerated in clinical studies.

Atossa’s patent estate now includes multiple U.S. patents with over 100 claims related to (Z)-endoxifen formulations and their clinical applications. The company is currently studying (Z)-endoxifen for both the treatment and prevention of breast cancer, including a metastatic breast cancer program announced earlier this year.

https://www.investing.com/news/company-news/atossa-therapeutics-secures-new-patent-for-breast-cancer-treatment-93CH-3995765

Novocure wins CE mark for its lung cancer treatment wearable

 Novocure (Baar, Switzerland) announced today that it has won a CE mark for its Optune Lua wearable device for treating metastatic non-small cell lung cancer.

The regulatory approval in the European Union comes approximately six months after Novocure secured FDA approval of the system, which uses tumor-treating fields (TTFields) to kill cancer cells. Through non-invasive, wearable arrays, Optune Lua uses TTFields to exert physical forces on the electrically charged components of the dividing cancer cells.

“Optune Lua is an innovative and urgently needed new approach for treating metastatic non-small cell lung cancer,” Dr. Joachim Aerts, an investigator in the system’s Phase 3 LUNAR clinical trial and professor of pulmonary oncology at the Erasmus MC Cancer Institute.

“There are few treatment options for people living with this aggressive cancer,” Aerts said in the news release. “In fact, the results from the Phase 3 trial of Optune Lua were the first in more than eight years to show a treatment providing a significant extension in overall survival. These results and the lack of systemic toxicity observed with Optune Lua provide patients with a promising new treatment option.”

Frank Leonard, president of Novocure Oncology, described the CE mark as a significant milestone in Novocure’s efforts to improve outcomes for people living with aggressive cancers.

“Tumor Treating Fields therapy has demonstrated effectiveness in multiple tumor types that have historically been very difficult to treat, including lung cancer. We believe the efficacy Optune Lua can offer, paired with its lack of systemic toxicity, has the potential to change the way late-stage lung cancer is treated,” Leonard said.

Novocure has initiated the local registration requirements for Optune Lua in Germany and is set to launch the system in the coming weeks.

https://www.massdevice.com/novocure-wins-ce-mark-for-its-lung-cancer-treatment-wearable/